Teva Pharmaceutical reports 5% fall in Q4 2022 revenue
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharmaceutical to Cut 14,000 Jobs - WSJ
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Buyers remorse or fraud? Teva and Mexican brothers slug it out over sour deal
Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug | Investor's Business Daily
Israeli drug company Teva reaches $4.3 billion settlement in US opioid lawsuits | The Times of Israel
Teva shares surge after announcing global opioid settlement
Israel's Teva to move US HQ from Pennsylvania to New Jersey | The Times of Israel
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Teva Faces New Class Action—But Could It Afford Another Se...
Teva Pharmaceuticals USA - News, Articles etc. - European Pharmaceutical Review
Teva reaches proposed $4.35 billion settlement of US opioid lawsuits | CNN Business
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva unifies pharmaceutical packaging worldwide | packagingdigest.com
Teva Pharmaceuticals Q2 2019 earnings preview | AlphaStreet
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
Teva to shutter IV bag manufacturing facility in Ashdod, Israel | Fierce Pharma
Teva Pharmaceuticals found liable in New York opioid trial - BBC News
Teva unifies pharmaceutical packaging worldwide | packagingdigest.com
Teva Launches New “Pivot to Growth” Strategy | Business Wire
Teva to pay $225M to settle cholesterol drug price-fixing charges | AP News
Suffering from missteps, drugmaker Teva struggles to heal own ills - The Times of Israel
Teva stock pops on Q2 results, CEO sees 'significant' potential for trio of branded drugs
